MiRXES
MiRXES is a Singapore-headquartered biotechnology company.
Mirxes reports $95.4m net loss ahead of IPO
Mirxes reports $95.4m net loss ahead of IPO
Costs of R&D and administrative activities widened last year’s losses.
Read Here
Advertise
Sign Up
Commentary
How commercial spaces must adapt to changing consumer expectations
AI, data centres, and the coming energy supercycle in Hong Kong
Reinsurance beyond borders: How Hong Kong can strengthen Asia’s risk-sharing architecture
Hong Kong hospitality insights: Robust investment, tourism expansion, and operational recovery
Hong Kong’s insurance boom is facing a financing test
In the age of AI, creativity is the decisive advantage
Hong Kong cleared stablecoins for take-off. Getting them to work across Asia is the hard part